The effect of the combination of bisphosphonates and conventional chemotherapy on bone metabolic markers in multiple myeloma patients

Hematology

Volumn 17, Issue 5, 2012, Pages 255-260

  Zhang, Xi ^a   Chang, Chunkang ^a   Zhao, Youshan ^a   Wu, Lingyun ^a   Zhang, Zheng ^a   Li, Xiao ^a  

^a SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

Author keywords

Multiple myeloma; Osteolytic bone lesion; Serum bone specific alkaline phosphatase; Urine N telopeptides of type I collagen

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; ANTINEOPLASTIC AGENT; CLODRONIC ACID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; EPIRUBICIN; MELPHALAN; NAVELBINE; PREDNISONE;

ADULT; AGED; ALKALINE PHOSPHATASE BONE ISOENZYME BLOOD LEVEL; AMINO TERMINAL TELOPEPTIDE URINE LEVEL; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHEMOLUMINESCENCE; CONTROLLED STUDY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC BONE DISEASE; MORNING DOSAGE; MULTIPLE MYELOMA; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN URINE LEVEL; REFERENCE VALUE;

ADULT; AGED; ALKALINE PHOSPHATASE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; COLLAGEN TYPE I; DIPHOSPHONATES; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM METASTASIS; OSTEOLYSIS; PEPTIDES; TUMOR MARKERS, BIOLOGICAL;

EID: 84866113308     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/1607845412Y.0000000021     Document Type: Article

References (20)

1. Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, et al The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma.
2. Orhan S. Myeloma bone disease: recent advances in biology, diagnosis, and treatment. Oncologist. 2009;14(3):276-283.
3. Michael Cohen M Jr. The new bone biology: pathologic, molecular, and clinical correlates. Article first published online: 13 November 2006 DOI:10.1002/ajmg.a.3136, 2006.
4. Van den WT, Huizing MT, Vermorken JB. Osteonecrosis of the jaw related to the use of bisphosphonates. Curr Opin Oncol. 2007;19(4):315-322.
5. Berenson JR. New advances in the biology and treatment of myeloma bone disease. Semin Hematol. 2001;382(Suppl. 3):15-20.
6. Kanis JA, McCloskey EV. Bisphosphonates in multiple myeloma. Cancer. 2000;88:3022-3032.
7. Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, et al International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467-1473.
8. Barille-Nion S, Bataille R. New insights in multiple myeloma-induced osteolysis. Leuk Lymphoma. 2003;44(9):1463-7.
9. Bataille R, Harousseau JL. Multiple myeloma. N Engl J Med. 1997;336(23):1657-1664.
10. Bataille R, Chappard D, Marcelli C, Dessauw P, Sany J, Baldet P, et al Mechanisms of bone destruction in multiple myeloma:the importance of an unbalanced process in determining the severity of lytic bone disease. Clin Oncol. 1989;7(12):1909-1914.
11. Jantunen E. Bisphosphonate therapy in multiple myeloma: past, present, future. Eur J Haematol. 2002;69(5-6):257-264.
12. Diamond T, Levy S, Day P, Barbagallo S, Manoharan A, Kwan YK, et al Biochemical, histornorphometric and densitometric changes in patients with multiple myeloma: effects of glucocorti-coid therapy and disease activity. Br J Haematol. 1997;97:641-648.
13. Mariette X, Khalifa P, Ravaud P, Frija J, Laval-Jeantet M, Chastan C, et al Bone densitometry in patients with multiple myeloma. Am J Med. 1992;93:595-597.
14. Holmes JA, Evans WD, Coles RJ, Ramsahoye B, Whittaker JA. Dual energy X-ray absorptiometry measurements of bone mineral density in myeloma. Eur J Haematol. 1994;53:309-311.
15. Heider U, Fleissner C, Zavrsk I, Kaiser M, Hecht M, Jakob C, et al Bone markers in multiple myeloma. Eur J Cancer. 2006; 42(11):1544-1553.
16. Bamford J, Sandercock P, Dennis M, Warlow C, Burn J. Classification and natural history of clinically identifiable sub-types of cerebral infarction. Lancet. 1991;337(8756):1521-1526.
17. Coleman RE. Emerging strategies in bone health management for the adjuvant patient. Semin Oncol. 2007;34(Suppl. 1):11-6.
18. Terpos E, Politou M, Szydlo R, Nadal E, Avery S, Olavarria E, et al Autologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL/osteoprotegerin ratio in paients with multiple myeloma. Leukemia. 2004;18(6):1420-1426.
19. Woitge HW, Pecherstorfer M, Horn E, Keck AV, Diel IJ, Bayer P, et al Serum bone sialoprotein as a marker of tumor burden and neoplastic bone involvement and as a prognostic factor in multiple myeloma. Br J Cancer. 2001;84(2):344-351.
20. Luftner D, Richter A, Geppert R, Wernecke KD, Possinger K. Normalisation of biochemical markers of bone formation corre- lateswith clinical benefit from therapy in metastatic breast cancer. Anticancer Res. 2003;23:1017-1026.